Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of intravenous dexlansoprazole for upper gastrointestinal bleeding caused by gastric and/or duodenal ulcers
CTR20210534Phase 2Completed
- Sponsor
- Nanjing Healthnice Pharmaceutical Technology
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexlansoprazole in upper gastrointestinal bleeding (UGIB), gastric ulcer, duodenal ulcer, sponsored by Nanjing Healthnice Pharmaceutical Technology. Started Oct 2023; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
upper gastrointestinal bleeding (UGIB)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on CTR20210534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210534.